XML 21 R9.htm IDEA: XBRL DOCUMENT
v3.25.0.1

INVENTORY | 9 Months Ended
--- | ---
Dec. 31, 2024
Inventory Disclosure [Abstract] |
Inventory Disclosure [Text Block] | NOTE 3 – INVENTORY
|  | (in thousands) |
|  | As of December 31, 2024 ($) |  |  | As of March 31, 2024 ($) |
Raw materials |  |  | 1,069 |  |  |  | 1,099 |
Work-in-Progress |  |  | - |  |  |  | - |
Finished goods |  |  | 364 |  |  |  | 441 |
Total |  |  | 1,433 |  |  |  | 1,540 |
Abnormal amounts of idle facility expense, freight, handling costs, scrap, and wasted material (spoilage) are expensed in the period they are incurred. During the nine months ended December 31, 2024, and 2023, the Company wrote off approximately $50 thousand and $746 thousand primarily related to obsolete and expired stock. We capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative use for the inventory in future research and development projects or other purposes. As of December 31, 2024, and March 31, 2024, our consolidated balance sheet reported approximately $392 thousand clinical trial-related inventory, respectively.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration